480 Biomedical Awarded $1 Million Phase II NHLBI Contract To Advance Bioresorbable Scaffold For Pediatric Pulmonary Artery Stenosis

WATERTOWN, Mass.--(BUSINESS WIRE)--480 Biomedical, Inc. today announced that it has been awarded Phase II funding from the National Heart, Lung, and Blood Institute (NHLBI) to continue the development of a bioresorbable, self-expanding scaffold to treat pediatric pulmonary artery stenosis (PAS). The product aims to address the serious challenges in treating cardiovascular stenosis in children with growing blood vessels. The scaffold’s unique design has the strength of a balloon-expandable metal stent to keep vessels open for an extended period before safely resorbing. The scaffold can also be delivered through a small catheter, which is essential for treating a pediatric population. This latest $1M round of funding will be used to further refine the design of the product and conduct preclinical testing.

Help employers find you! Check out all the jobs and post your resume.